Stay updated with breaking news from Dementia Due. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation - Interim Data: Study Achieves Primary End Point Demonstrating...
New efficacy data reported for pivotal Study 213 shows significant, clinically meaningful improvements in agitation symptoms.Agitation symptoms negatively impact functioning, disease progression, quality of life and care for about half of Alzheimer’s dementia patients – and are a consistent predictor of nursing home...
PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--May 10, 2023--
REXULTI is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s diseasePRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Lundbeck LLC (Lundbeck) announce the U.S. Food and Drug Administration (FDA) h...
REXULTI is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s diseasePRINCETON, N.J ...